Table 2.
Pharmacological and device therapy details of the study participants.
| Characteristic | All subjects (5590) |
Survival status at 1 year after the index visit |
||
|---|---|---|---|---|
| Alive (4606) | Dead (984) | P-value | ||
| Drugsa | ||||
| Beta blockers | 4574 (81.8) | 3824 (83.0) | 750 (76.2) | <0.001 |
| ACEI | 2796 (50.0) | 2342 (50.8) | 454 (46.1) | 0.007 |
| ARB | 953 (17.0) | 772 (16.8) | 181 (18.4) | 0.22 |
| ACEI or ARB | 3680 (65.8) | 3062 (66.5) | 618 (62.8) | 0.027 |
| Loop diuretics | 4441 (79.4) | 3610 (78.4) | 831 (84.5) | <0.001 |
| Antiarrhythmic drugs | 677/4891 (13.8) | 533/4080 (13.1) | 144/811 (17.8) | <0.001 |
| Ivabradine | 971/4892 (19.8) | 786/4081 (19.3) | 185/811 (22.8) | 0.021 |
| Statin | 4205 (75.2) | 3491 (75.8) | 714 (72.6) | 0.033 |
| Digoxin | 247/4548 (5.4) | 195/3867 (5.0) | 52/681 (7.6) | 0.006 |
| Cardiac rhythm device therapy | ||||
| Overall usage | 585 (10.5) | 493 (10.7) | 92 (9.3) | 0.21 |
| Device type | 0.25 | |||
| CRT/CRTD | 240 (4.3) | 207 (4.5) | 33 (3.4) | |
| Dual-chamber pacemaker | 106 (1.9) | 84 (1.8) | 22 (2.2) | |
| AICD | 239 (4.3) | 202 (4.4) | 37 (3.8) | |
All values are reported as actual numbers with percentages in parentheses. Bold values in P-value column indicate statistically significant differences.
ACEI, angiotensin-converting enzyme inhibitor; AICD, automatic implantable cardioverter defibrillator; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; CRTD, cardiac resynchronization therapy with defibrillator.
a
The medication details represent treatment advise provided at the clinic, and it is not known whether these medications were continued as advised, changed, or stopped during the subsequent one year.